Pregled bibliografske jedinice broj: 124916
What's new in topical therapy
What's new in topical therapy // Acta Dermatovenerologica Croatica / Lipozenčić, Jasna (ur.).
Zagreb: Medicinska naklada, 2003. str. 102-104 (predavanje, međunarodna recenzija, cjeloviti rad (in extenso), stručni)
CROSBI ID: 124916 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
What's new in topical therapy
Autori
Lipozenčić, Jasna
Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), stručni
Izvornik
Acta Dermatovenerologica Croatica
/ Lipozenčić, Jasna - Zagreb : Medicinska naklada, 2003, 102-104
Skup
Topical procedures, innovations and mistreatments in dermatovenerology
Mjesto i datum
NP Plitvička jezera, Hrvatska, 29.05.2003. - 31.05.2003
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Laboratory research; tacrolimus; pimecrolimus; topical steroids; local treatments; dermatologic conditions
Sažetak
There is a paucity of research laboratory commonly used local treatments in general. Particular attention is given to new local therapy options. New formulations such as pimecrolimus, are being developed in the treatment of dermatological conditions. Pimecrolimus (0.2% ; 0.6% ; 1% vehicle cream-Eldiel® ; (ASK 981) in the treatment of atopic dermatitis, this newer calcineurin inhibitor has also been shown in anti-inflammatory potency and not to induce skin atrophy. Pimecrolimus is closely related to tacrolimus. Tacrolimus and pimecrolimus share the same cellular binding targets and mechanism of action. Tacrolimus ointment (0.03% or 0.1%-Protopic® ; ), a topical inhibitor of the phosphatase calcineurin has recently been approved in the USA for use in the treatment of moderate to severe atopic dermatitis. It is the first nonsteroid topical immune suppressant that is not one of the hydrocortisone deviates important allies in dermatology for nearly 50 years. Although tacrolimus is less able to penetrate thick skin than glucocorticosteroids it does not cause dermal atrophy, an important advantage. Tacrolimus ointment for facial lesions of chronic actinic dermatitis appears to be effective and well tolerated. In general, tacrolimus will have an upper hand therapeutically because is safety in treating facial dermatoses (psoriasis, seborrheic dermatitis, allergic contact dermatitis, rosacea), alopecia areata and lichen planus. However, topical steroids will remain more economical than tacrolimus because in many cases they are available as generics.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA